| 第一章節 | | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | | 普通股 | 股份類別 | H | | | 於香港聯交所上市 | | 是 | | | | | 證券代號 (如上市) | | 06826 | 說明 | H 股 | | | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | | 庫存股份變動 | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | | 庫存股份數目 | | 每股發行/出售價 (註4) | | 已發行股份總數 | | | 於下列日期開始時的結存(註1) | | 2025年12月24日 | | 38,529,240 | | | | 0 | | | | 38,529,240 | ...

上海昊海生物科技有限公司于2025年12月22日购回17,000股H股，价格介乎25.54至25.60港元，总代价 434,916港元，股份拟注销。此次购回依据2025年6月10日通过的授权进行，累计已购回2,516,600股，占 当时已发行股份的6.4294%。 截至2025年12月26日收盘，昊海生科（688366）报收于44.63元，较上周的44.83元下跌0.45%。本周， 昊海生科12月22日盘中最高价报45.15元。12月24日盘中最低价报44.04元，股价触及近一年最低点。昊 海生科当前最新总市值103.8亿元，在医疗器械板块市值排名33/127，在两市A股市值排名1854/5178。 本周关注点 公司公告汇总 上海昊海生物科技股份有限公司公告，控股股东、实际控制人之一蒋伟先生因非本公司事项，收到中国 证监会《行政处罚决定书》（[2025]151号）。因其存在内幕交易及建议他人买卖证券行为，证监会决 定没收其违法所得4,709,741.41元，并处以14,629,224.23元罚款。该事项与公司无关，蒋伟不参与公司日 常经营，公司生产经营正常开展。 以上内容为证券之星据公开信息整理，由AI算法生 ...

Core Viewpoint - The insider trading case involving Jiang Wei, the actual controller of Haohai Biological Technology (688366.SH), has concluded with a total penalty of 19.34 million yuan, highlighting governance concerns within the company as it faces growth challenges and declining performance [1][2][5]. Group 1: Insider Trading Case - Jiang Wei was penalized by the China Securities Regulatory Commission (CSRC) for insider trading and advising others to trade securities, resulting in a total fine and confiscation of 19.34 million yuan [1][5]. - The investigation lasted seven months, reflecting the current regulatory environment's strict stance against insider trading, with half of the CSRC's administrative penalties this year related to such cases [5][7]. - Jiang Wei has never held a position in the listed company and does not participate in daily operations, yet he and his wife control 45.82% of the company's shares [1][5]. Group 2: Company Performance and Governance - Haohai Biological Technology is experiencing a growth bottleneck, with 2024 revenue at 2.698 billion yuan, a mere 1.64% increase, marking the first single-digit growth since 2021 [2][10]. - The company has seen a decline in both revenue and net profit in the first three quarters of 2025, with revenue down 8.47% and net profit down over 10% [2]. - The governance structure is questioned as Jiang Wei's influence persists despite his absence from operational roles, raising concerns about the "behind-the-scenes boss" model [8][12]. Group 3: Business Challenges - The company faces significant challenges in its ophthalmology segment, with revenue from artificial lenses down 14.06% and viscoelastic agents down 19.53% due to centralized procurement policies [10]. - Although the aesthetic medicine segment remains a growth driver, the growth rate of hyaluronic acid products has sharply decreased from 95.45% in 2023 to 23.23% [10]. - Haohai is attempting to diversify by acquiring a 19.8% stake in Ruijie Biological for 38.35 million yuan, despite the target company being in a loss-making state [10].

Core Viewpoint - Shanghai Haohai Biological Technology Co., Ltd. announced that its actual controller, Mr. Jiang Wei, received regulatory penalties for personal actions in the securities market, which has drawn market attention [1][4]. Group 1: Regulatory Actions - Mr. Jiang Wei was penalized by the China Securities Regulatory Commission for insider trading and advising others to trade securities, with the investigation process taking several months from the initial notice to the final decision [1][4]. - The company clarified that the penalties are directed at Mr. Jiang personally and are unrelated to the operations of Haohai Biological, emphasizing that he does not participate in daily management [1][4]. Group 2: Company Operations and Governance - Despite the personal nature of the incident, it has prompted scrutiny of the company's governance structure and future development, as Haohai Biological is a well-known entity in the biomedical materials sector and the first pharmaceutical company listed on both the Hong Kong Stock Exchange and the STAR Market [2][5]. - The long-term value of the company is contingent upon the development potential of its core business and market competitiveness, particularly in the fields of medical aesthetics and ophthalmology, which are recognized for their growth prospects but also face challenges such as industry competition and market demand fluctuations [2][5][6]. - The management's focus should be on maintaining stable operations while driving technological innovation and strengthening market position to gain long-term trust from the capital market, which is more critical than addressing a single incident [2][6].

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 作为曾与华熙生物、爱美客齐名的国内"医美三剑客"之一，昊海生科凭借A+H双融资平台的资本优势及 在医美、眼科等高景气赛道的布局，一度成为市场瞩目的明星企业。 然而眼下，与其昔日光环相伴的，是核心业务增长引擎集体失速，为寻求突围而进行的并购交易疑窦丛 生，公司治理层面问题频发等。 业绩全面失速仍慷慨分红 控股股东成最大受益者 从业绩表现看，公司营收与净利润已连续多个季度同比下滑。2025年前三季度，公司实现营业收入 18.99亿元，同比下降8.47%；实现归母净利润3.05亿元，同比下降10.63%；实现扣非归母净利润2.55亿 元，同比下降20.75%。 结合业务看，营收占比最大的医美板块增长疲态已有所显现。核心产品玻尿酸销售收入上半年仅为3.47 亿元，同比大幅下滑16.8%。尽管公司推出了第四代有机交联玻尿酸等新产品，但在行业整体消费需求 不足、价格竞争日趋白热化以及监管环境变化的背景下，明星产品线增长乏力，短期内难以看到强劲的 复苏拐点。 眼科业务作为公司战略重心则遭遇政策与市场的双重夹击。一方面，2023年11月，业务核心产品人 ...

格隆汇12月23日丨昊海生科(688366.SH)公布，公司控股股东、实际控制人之一蒋伟此前因非本公司事 项，收到中国证监会出具的《行政处罚事先告知书》。近日，公司收到蒋伟告知，获悉其因前述事项， 收到了中国证监会出具的《行政处罚决定书》。行政处罚决定书的主要内容为：因蒋伟内幕交易、建议 他人买卖证券行为，中国证监会决定没收其违法所得4709741.41元，并对其处以14629224.23元罚款。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 呈交日期： 2025年12月24日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06826 | 說明 H 股 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 ...

格隆汇12月24日丨昊海生物科技(06826.HK)发布公告，2025年12月24日耗资43.50万港元回购1.71万股， 回购价格每股25.32-25.54港元。 ...

智通财经APP讯，昊海生物科技(06826)发布公告，于2025年12月24日斥资43.5万港元回购1.71万股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 呈交日期： 2025年12月24日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06826 | 說明 H 股 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 ...